BCWORLD PHARM. Co. Ltd (200780) - Net Assets
Based on the latest financial reports, BCWORLD PHARM. Co. Ltd (200780) has net assets worth ₩72.50 Billion KRW (≈ $49.13 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩173.79 Billion ≈ $117.78 Million USD) and total liabilities (₩101.30 Billion ≈ $68.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BCWORLD PHARM. Co. Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩72.50 Billion |
| % of Total Assets | 41.71% |
| Annual Growth Rate | 1.44% |
| 5-Year Change | -24.61% |
| 10-Year Change | N/A |
| Growth Volatility | 9.47 |
BCWORLD PHARM. Co. Ltd - Net Assets Trend (2015–2024)
This chart illustrates how BCWORLD PHARM. Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of BCWORLD PHARM. Co. Ltd for the complete picture of this company's asset base.
Annual Net Assets for BCWORLD PHARM. Co. Ltd (2015–2024)
The table below shows the annual net assets of BCWORLD PHARM. Co. Ltd from 2015 to 2024. For live valuation and market cap data, see how much is BCWORLD PHARM. Co. Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩76.67 Billion ≈ $51.96 Million |
-6.09% |
| 2023-12-31 | ₩81.64 Billion ≈ $55.33 Million |
+2.63% |
| 2022-12-31 | ₩79.55 Billion ≈ $53.91 Million |
-2.34% |
| 2021-12-31 | ₩81.46 Billion ≈ $55.20 Million |
-19.90% |
| 2020-12-31 | ₩101.69 Billion ≈ $68.92 Million |
+4.58% |
| 2019-12-31 | ₩97.24 Billion ≈ $65.90 Million |
+7.94% |
| 2018-12-31 | ₩90.09 Billion ≈ $61.05 Million |
+10.91% |
| 2017-12-31 | ₩81.23 Billion ≈ $55.05 Million |
+9.95% |
| 2016-12-31 | ₩73.88 Billion ≈ $50.06 Million |
+9.61% |
| 2015-12-31 | ₩67.40 Billion ≈ $45.68 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BCWORLD PHARM. Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 23.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩41.52 Billion | 54.16% |
| Common Stock | ₩1.78 Billion | 2.32% |
| Other Components | ₩33.37 Billion | 43.52% |
| Total Equity | ₩76.67 Billion | 100.00% |
BCWORLD PHARM. Co. Ltd Competitors by Market Cap
The table below lists competitors of BCWORLD PHARM. Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MPC Energy Solutions NV
OL:MPCES
|
$30.55 Million |
|
Green Critical Minerals Ltd
AU:GCM
|
$30.55 Million |
|
Heeros Oyj
HE:HEEROS
|
$30.56 Million |
|
D P Wires Limited
NSE:DPWIRES
|
$30.57 Million |
|
HLscience Co. Ltd
KQ:239610
|
$30.55 Million |
|
Focus Graphite Inc
V:FMS
|
$30.54 Million |
|
Carbochim SA
RO:CBC
|
$30.54 Million |
|
Central Motek Co Ltd
KO:308170
|
$30.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BCWORLD PHARM. Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 81,642,992,680 to 76,667,758,590, a change of -4,975,234,090 (-6.1%).
- Net loss of 4,432,502,600 reduced equity.
- Dividend payments of 542,731,500 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-4.43 Billion | -5.78% |
| Dividends Paid | ₩542.73 Million | -0.71% |
| Other Changes | ₩10.00 | +0.0% |
| Total Change | ₩- | -6.09% |
Book Value vs Market Value Analysis
This analysis compares BCWORLD PHARM. Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.53x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩9607.15 | ₩4410.00 | x |
| 2017-12-31 | ₩9604.31 | ₩4410.00 | x |
| 2018-12-31 | ₩10653.52 | ₩4410.00 | x |
| 2019-12-31 | ₩11546.65 | ₩4410.00 | x |
| 2020-12-31 | ₩11909.98 | ₩4410.00 | x |
| 2021-12-31 | ₩9539.98 | ₩4410.00 | x |
| 2022-12-31 | ₩9427.18 | ₩4410.00 | x |
| 2023-12-31 | ₩8795.44 | ₩4410.00 | x |
| 2024-12-31 | ₩8259.45 | ₩4410.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BCWORLD PHARM. Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.92%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 2.30x
- Recent ROE (-5.78%) is below the historical average (4.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 9.39% | 15.28% | 0.52x | 1.18x | ₩-413.65 Million |
| 2016 | 8.76% | 14.18% | 0.47x | 1.31x | ₩-912.82 Million |
| 2017 | 9.95% | 16.10% | 0.42x | 1.46x | ₩-40.15 Million |
| 2018 | 9.63% | 15.74% | 0.34x | 1.80x | ₩-333.75 Million |
| 2019 | 6.23% | 11.71% | 0.30x | 1.78x | ₩-3.67 Billion |
| 2020 | 4.58% | 8.19% | 0.30x | 1.90x | ₩-5.51 Billion |
| 2021 | -2.26% | -2.97% | 0.35x | 2.20x | ₩-9.99 Billion |
| 2022 | 0.35% | 0.39% | 0.40x | 2.30x | ₩-7.67 Billion |
| 2023 | 3.23% | 3.51% | 0.41x | 2.26x | ₩-5.53 Billion |
| 2024 | -5.78% | -5.92% | 0.42x | 2.30x | ₩-12.10 Billion |
Industry Comparison
This section compares BCWORLD PHARM. Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $51,736,139,858
- Average return on equity (ROE) among peers: -1.15%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BCWORLD PHARM. Co. Ltd (200780) | ₩72.50 Billion | 9.39% | 1.40x | $30.55 Million |
| PharmGen Science Inc (004720) | $25.73 Billion | 0.00% | 0.94x | $61.63 Million |
| Korean Drug Co. Ltd (014570) | $65.05 Billion | 5.99% | 0.17x | $30.25 Million |
| Chorokbaem Healthcare Co Ltd (118000) | $18.71 Billion | -15.55% | 0.96x | $242.13 Million |
| Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) | $97.46 Billion | 4.95% | 1.31x | $131.08 Million |
About BCWORLD PHARM. Co. Ltd
BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea. The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive expectorant, vaginitis treatment, anti-tuberc… Read more